LEVEMIR FLEXPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LEVEMIR FLEXPEN (LEVEMIR FLEXPEN).
Long-acting insulin analog that activates insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis.
| Metabolism | Metabolized via insulin-degrading enzyme (IDE); less susceptible to hepatic degradation. |
| Excretion | Renal (30-40% unchanged), remainder hepatically metabolized and excreted in bile/feces; negligible fecal elimination of parent drug. |
| Half-life | Terminal elimination half-life approximately 5-7 hours in children (<6 years: 3-4 hours); provides flat, prolonged pharmacokinetic profile over 24 hours with no pronounced peak. |
| Protein binding | >98% bound to albumin. |
| Volume of Distribution | 0.12 L/kg (intravenous); indicates distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous: approximately 60-65% (range 44-81% depending on injection site). |
| Onset of Action | Subcutaneous: 3-4 hours after injection. |
| Duration of Action | Up to 24 hours (range 16-24 hours); requires once-daily fixed dosing; less pronounced peak than NPH. |
Subcutaneous injection. Initial dose: 0.2-0.5 units/kg/day once daily or divided into two doses. Titrate by 2-10 units once or twice weekly based on glycemic control. Maximum dose not defined.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment required, but increased risk of hypoglycemia. Monitor glucose closely; dose reduction may be necessary. |
| Liver impairment | No specific Child-Pugh based guidelines. Use with caution; dose adjustment may be needed due to altered glucose metabolism. |
| Pediatric use | Subcutaneous injection. For type 1 diabetes: initial 0.1-0.2 units/kg/day once daily or divided. For type 2 diabetes: initial 0.2-0.5 units/kg/day. Titrate based on glycemic response. |
| Geriatric use | Start at lower doses (e.g., 0.1-0.2 units/kg/day) due to increased risk of hypoglycemia. Titrate cautiously, monitor renal function and glucose closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LEVEMIR FLEXPEN (LEVEMIR FLEXPEN).
| Breastfeeding | Insulin detemir is excreted in human breast milk in negligible amounts. The milk-to-plasma ratio is approximately 0.1. It is considered compatible with breastfeeding, as insulin is a peptide that is likely digested in the infant's gastrointestinal tract and poses no known risk. However, caution should be exercised and glucose monitoring of the mother may be necessary. |
| Teratogenic Risk | Insulin detemir (Levemir) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, there is no evidence of increased risk of fetal malformations; however, poor glycemic control is associated with fetal risks including congenital anomalies, macrosomia, and neonatal hypoglycemia. Insulin detemir does not cross the placenta in significant amounts. Close monitoring of glucose control is recommended throughout pregnancy. |
■ FDA Black Box Warning
Never share a Levemir FlexPen between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Serious Effects |
["Hypoglycemia","Hypersensitivity to insulin detemir or any excipients"]
| Precautions | ["Hypoglycemia is the most common adverse reaction","Monitor blood glucose; adjust dose with changes in renal/hepatic function","Exercise caution in patients with hypokalemia or during illness/stress"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently, including fasting and postprandial glucose. Assess hemoglobin A1c periodically. During labor and delivery, monitor glucose closely to avoid maternal hypoglycemia. Fetal monitoring includes ultrasound for growth and amniotic fluid volume, and fetal non-stress tests or biophysical profiles as indicated. |
| Fertility Effects | Insulin detemir has no known direct effects on fertility. However, uncontrolled diabetes can impair fertility and increase pregnancy complications. Achieving good glycemic control may improve fertility outcomes. |